BioStock: BioInvent anticipates a continued data-rich 2024

With cash reserves surpassing one billion SEK, providing significant operational flexibility, and anticipating results from several of its clinical programs, BioInvent is entering an eventful autumn. In the H1 interim report, CEO Martin Welschof conveys optimism about the company’s future developing novel cancer treatments.
– The second quarter was very busy and highly productive, and we will continue this momentum into the second half of the year.

Read the article at biostock.se:

https://www.biostock.se/en/2024/09/bioinvent-anticipates-a-continued-data-rich-2024/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/